COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Universitaire Ziekenhuizen Leuven
Updated on 25 January 2021
ct scan
coronary artery disease
coronary artery stenosis
aortic valve stenosis
transcatheter aortic valve implantation
arterial disease


Aortic stenosis (AS) is the most common primary valve disease leading to surgery or catheter intervention in Europe, with a growing prevalence due to the aging population. Severe AS is associated with significant morbidity and mortality and is treated by surgical valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI). However, significant coronary artery disease (CAD) is reported in more than 60% of patients with AS, and this concomitant CAD needs to be correctly assessed because untreated significant CAD is associated with adverse outcomes. Current guidelines recommend intra-coronary pressure measurement using either fractional flow reserve (FFR) or non-hyperemic pressure ratios (NHPR) for the assessment of intermediate coronary artery lesions before revascularization. However, correctly identifying hemodynamically significant coronary stenoses by FFR or NHPR is difficult in patients with AS because of the hypertrophic remodeling related to the valve pathology, which interferes with coronary blood flow in the microcirculation and reduces the accuracy of FFR and NHPR. This has resulted in substantial controversy in this field of coronary artery disease and there is currently no clear guideline for the management of AS patients with concomitant CAD. Recent technological advances now permit the concomitant evaluation of FFR/NHPR and microcirculatory function at the time of cardiac catheterization. Using this technology, we will simultaneously evaluate the hemodynamic significance of coronary stenoses (using FFR and a NHPR - Resting Full cycle Ratio [RFR]) and the microcirculatory function (Index of Microcirculatory Resistance, IMR) in patients with AS and CAD prior to SAVR/TAVI. Eighty patients with AS and intermediate CAD will be included in the study. During routine pre-valve replacement cardiac catheterization, measurement of intermediate CAD lesions (by FFR and RFR) and IMR will be performed using new software. These measures of CAD severity will be compared with a gold standard non-invasive test (single photon emission computed tomography [SPECT]). This will validate the use of RFR and determine if IMR can be used to improve the ischemia prediction of FFR. Subsequently, when these patients undergo a post-intervention (whether SAVR or TAVI) evaluation 6 months after valve replacement, the effect of valve replacement on FFR, RFR and IMR will be determined.

Condition Coronary Artery Disease, Coronary Artery Disease, Aortic Stenosis, Coronary heart disease, VALVULAR HEART DISEASE, Heart Valve Disease, Cardiac Ischemia, Heart Valve Disease, Myocardial Ischemia, aortic valve stenosis
Clinical Study IdentifierNCT04420325
SponsorUniversitaire Ziekenhuizen Leuven
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

\. Patient undergoing the procedure is older than 18 years, has severe aortic valve stenosis (according to ESC guidelines) and is planned for cardiac catheterization as part of the pre-operative (SAVR) or pre-percutaneous (TAVI) work up. 2. The patient has an intermediate (50-90%) coronary lesion that requires further evaluation. 3. The patient undergoing the procedure is male, or if female, has no childbearing potential or is not pregnant

Exclusion Criteria

The procedure is an emergency and/or the patient is unstable
Pregnancy or lactation
Haemodynamically unstable patients
Killip class III-IV heart failure
Previous coronary artery by-pass in the artery being assessed
Contra-indications for adenosine administration: severe asthma or pre-existing type 2 AV-block
No significant coronary artery disease (<50% stenosis on angiography)
Critical coronary artery disease deemed by the Heart Team to require immediate revascularization
Patients will be excluded from the SPECT study (secondary objective) if they have a left main coronary stenosis >50%, triple vessel disease, previous myocardial infarction in the same coronary artery & tandem lesions (separated by >10mm) requiring independent evaluation in the same coronary artery since these factors interfere with the SPECT analysis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note